Conference Track

Hematologic Malignancies

Source: CCO Independent Conference Coverage of the 2009 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Id-KLH Vaccine Improves DFS and Shows Good Tolerability in Patients With Follicular Lymphoma
High-Dose Daunorubicin Induction Improves OS in Acute Myeloid Leukemia
Galectin-3 Inhibitor GCS-100 Shows Single-Agent Activity in Elderly Patients With Relapsed Chronic Lymphocytic Leukemia
Omacetaxine Active With Minimal Toxicity in T315I-Positive CML Patients Who Failed Imatinib
Single-Agent Ofatumumab Produces Clinical Benefit in Patients With Double-Refractory or Bulky Fludarabine-Refractory CLL
Rituximab Added To ACVBP Produces Encouraging Outcomes in DLBCL
CORAL Study: R-ICE and R-DHAP Induction Therapy Produce Comparable Outcomes in Patients With Relapsed DLBCL
Prolonged Rituximab Therapy Extends EFS and Is Well Tolerated in Patients With Follicular Lymphoma
VMPT Improves Response but Not PFS Compared With VMP in Newly Diagnosed, Elderly Patients With Multiple Myeloma
Bortezomib, Intravenous Cyclophosphamide, Dexamethasone Induction Therapy Effective in Younger Patients With Newly Diagnosed Multiple Myeloma
Phase III Trial: Pixantrone Improves Outcomes in Heavily Pretreated Patients With Non-Hodgkin’s Lymphoma
Weekly Bortezomib Combined With Rituximab Shows Encouraging Activity in Waldenström’s Macroglobulinemia
Combination Regimen Lenalidomide, Bortezomib, Dexamethasone Active in Relapsed/Refractory Multiple Myeloma

Expert Analysis

ASCO 2009: Hematologic Malignancies Expert Analysis

Faculty:

Kenneth Anderson, MD
Andre Goy, MD, MPH
Susan M. O'Brien, MD

Edward A. Stadtmauer, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Apply recent clinical trial results regarding transplantation and current and novel agents in the treatment of patients with multiple myeloma
Discuss data from clinical trials of monotherapy and combination regimens for the treatment of lymphomas
Cite novel approaches and emerging agents in the clinical management of leukemias

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: August 03, 2009

Expiration Date: August 02, 2010

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing contact hours

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.